5 completed, 4 terminated, 1 active not recruiting, 1 unknown. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 5, Terminated 4, Active not recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Sunitinib Malate: new trials by email Literature Review of Sunitinib Malate trials Research Report on Sunitinib Malate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab, Sunitinib Malate - Non-Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Exelixis | 317 | 2023-01-01 | 2026-07-29 |
| Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) Sunitinib Malate, TAS 102 - Colorectal Cancer, Metastasis | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 60 | 2019-10-01 | 2020-11-13 |
| Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer sunitinib malate, Placebo, transarterial chemoembolization - Liver Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 78 | 2010-07-01 | 2022-03-18 |
| Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer sunitinib malate, sorafenib - Carcinoma, Hepatocellular | Phase 3 | Terminated | Pfizer | 1075 | 2008-07-01 | 2013-01-14 |
| Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment - Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 210 | 2008-06-15 | 2026-06-23 |
| A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Sunitinib malate, Placebo - Kidney Neoplasms | Phase 3 | Completed | Pfizer | 674 | 2007-08-01 | 2018-09-21 |
| A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors sunitinib malate, Placebo - Carcinoma, Islet Cell, Carcinoma, Pancreas | Phase 3 | Terminated | Pfizer | 171 | 2007-06-01 | 2010-10-11 |
| Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors sunitinib malate, imatinib mesylate - Gastrointestinal Stromal Tumor | Phase 3 | Terminated | Pfizer | 69 | 2007-06-01 | 2011-03-17 |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer Sunitinib malate, Taxotere - Breast Neoplasms | Phase 3 | Completed | Pfizer | 594 | 2007-02-01 | 2012-07-19 |
| A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine Capecitabine, Sunitinib malate - Breast Neoplasms | Phase 3 | Terminated | Pfizer | 482 | 2006-11-01 | 2012-06-25 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment - Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 1943 | 2006-04-24 | 2026-06-23 |
Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Islet Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Pfizer (6) · National Cancer Institute (NCI) (2) · Amsterdam UMC, location VUmc (1) · Exelixis (1) · Federation Francophone de Cancerologie Digestive (1)
United States (8) · France (7) · Germany (7) · Italy (7) · South Korea (7) · Spain (7) · United Kingdom (7) · Australia (6) · Canada (5) · Hong Kong (4) · Poland (4) · Taiwan (4) · Turkey (Türkiye) (4) · Argentina (3) · Belgium (3)
Henk Verheul, Prof. M.D. (1) · Mark A Socinski (1) · Mohamed Hebbar, MD (1) · Naomi S Balzer-Haas (1)
PMID 20203173, PMID 21306237, PMID 24081937, PMID 26969090, PMID 27718781, PMID 27836885, PMID 27924459, PMID 28161554, PMID 28278333, PMID 28945839, PMID 28967554, PMID 29161241, PMID 29374054, PMID 29773662, PMID 30412222, PMID 31703971, PMID 32576496, PMID 32582758, PMID 33028084, PMID 33411058, PMID 34405965, PMID 34480522, PMID 35226112, PMID 36216827, PMID 37433436, PMID 40008409, PMID 40973474
U10CA021115 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1)